From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation

Our guest this week is Dr. Louise von Stechow with the first of a three-part deep dive into the longevity industry—the part of biotech trying to turn aging biology into actual drugs rather than supplement stacks and n=1 experiments. Louise is a pharma and biotech strategy consultant, host of the BioRevolution Podcast, and a regular BiopharmaTrend.com co…